VERU News and Press, Veru Inc. From 02/15/24

2024-02-15 07:49:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecos...

2024-02-08 13:36:10 ET Veru Inc. (VERU) Q1 2024 Earnings Conference Call February 8, 2024, 8:00 a.m. ET Company Participants Mitchell Steiner - CEO Michele Greco - CFO Dr. Gary Barnette - Chief Scientific Officer Michael Purvis - EVP, General Counsel & Co...

2024-02-08 06:31:44 ET More on Veru Veru eyes better weight loss drugs as FDA clears Phase 2 trial Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru Read the full article on Seeking Alpha ...

—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone— —Company to initiate Phase 2b obesity study by April 2024— ...

Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...

2024-02-07 12:05:09 ET More on Veru Veru eyes better weight loss drugs as FDA clears Phase 2 trial Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru Read the full article on Seeking Alpha ...

2024-02-06 15:27:22 ET More on Veru Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru Read the full article on Seeking Alpha For further details see: Veru eyes better weight loss drugs as ...

FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone Randomized Phase 2b clinical trial aims to show enobosarm preserves muscle and physical...

MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, ...

MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference cal...